Candriam SCA’s NovoCure NVCR Stock Holding History

Candriam SCA’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3	Closed	–	–	809
2022 Q1	$0	Buy	+3	New	+$221	﹤0.01%	837
2021 Q4	–	Sell	-3	Closed	–	–	847
2021 Q3	$0	Hold	3	–	–	﹤0.01%	896
2021 Q2	$1K	Buy	3 +1	+50%	+$195	﹤0.01%	876
2021 Q1	$0	Sell	2 -2	-50%	-$316	﹤0.01%	816
2020 Q4	$1K	Sell	4 -6	-60%	-$821	﹤0.01%	803
2020 Q3	$1K	Buy	10 +1	+11%	+$80	﹤0.01%	800
2020 Q2	$1K	Buy	9 +1	+13%	+$66	﹤0.01%	797
2020 Q1	$1K	Buy	+8	New	+$632	﹤0.01%	787

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Candriam SCA's NVCR Position: Q2 2022 in Review

Candriam SCA sold out of NovoCure (NVCR) in Q2 2022, closing a stake of 3 shares.

Candriam SCA first reported a position in NVCR in Q1 2020 and held it in 8 quarters. The position peaked at $1K in Q2 2021. 316 funds tracked by Wall St. Rank hold NVCR as of Q2 2022.

Candriam SCA reported no remaining NovoCure position as of Q2 2022 after selling out during the quarter.
Candriam SCA sold 3 NovoCure shares in Q2 2022.
Candriam SCA first reported a position in NovoCure in Q1 2020 and held it in 8 quarters.
Candriam SCA's NovoCure position peaked at $1K in Q2 2021.
316 funds tracked by Wall St. Rank held NovoCure as of Q2 2022.

Based on Candriam SCA's 13F filing for Q2 2022, filed 3 Aug 2022.